Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Park, Noh Jin ^a   Wang, Xiuqiang ^a   Diaz, Angelica ^a   Goos Root, Dana M ^a   Bock, Christopher ^b   Vaught, Jonathan D ^b   Sun, Weimin ^a   Strom, Charles M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b SomaLogic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; PANITUMUMAB;

ACCURACY; ARTICLE; BINDING AFFINITY; BINDING SITE; CROSS REACTION; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; SLOW OFF RATE MODIFIED APTAMER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REPRODUCIBILITY OF RESULTS;

EID: 84882717165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071703     Document Type: Article

References (23)

1. Hynes NE, MacDonald G, (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
2. Xu YH, Richert N, Ito S, Merlino GT, Pastan I, (1984) Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 81: 7308-7312.
3. Zabrecky JR, Lam T, McKenzie SJ, Carney W, (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720.
4. Carney WP, (2007) Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn 7: 309-319.
5. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531.
6. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, et al. (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13: 33-42.
7. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956.
8. Bardelli A, Siena S, (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261.
9. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, et al. (2012) Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223.
10. Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, et al. (2011) Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol 11: 17.
11. Planque S, Zhou YX, Nishiyama Y, Sinha M, O'Connor-Mccourt M, et al. (2003) Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice. FASEB J 17: 136-143.
12. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, et al. (2004) Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 6006-6012.
13. Ellington AD, Szostak JW, (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
14. Tuerk C, Gold L, (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
15. Vaught JD, Bock C, Carter J, Fitzwater T, Otis M, et al. (2010) Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132: 4141-4151.
16. Gold L, Ayers D, Bertino J, Bock C, Bock A, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5: e15004.
17. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, et al. (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6: e26332.
18. Arteaga ME, Ledon N, Casaco A, Pardo B, Garcia M, et al. (2007) Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab. Cancer Biol Ther 6: 1390-1395.
19. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
20. Esposito CL, Catuogno S, de Franciscis V, Cerchia L, (2011) New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496.
21. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
22. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A, (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28: 863-867.
23. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117.